The Wellspan Institutional Criteria for *Clostridium difficile* testing are:

(1) to submit stool specimens only from patients with unexplained and new onset diarrhea with ≥ 3 unformed stools in a 24-hour period;

(2) not to submit stool specimens on patients receiving laxatives;

(3) not to routinely test neonates or infants ≤ 12 months of age with diarrhea due to the high prevalence of asymptomatic carriage of toxigenic *C. difficile*;

(4) not to perform repeat testing within 7 days during the same episode of diarrhea;

(5) not to test stool from asymptomatic patients (except for epidemiological studies); and

(6) to continue to use a stand-alone, sensitive and specific nucleic acid amplification test (NAAT) to confirm the diagnosis of *C. difficile* infection (CDI). The test being performed by Wellspan Laboratory Services at ECH, GH, GSH, and YH is the *C. difficile* PCR Assay that detects toxigenic *C. difficile*. The assay is manufactured by Cepheid and tested on the GeneXpert or Infinity instrument.

These criteria conform to the Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). The criteria have been reviewed by the Wellspan Infectious Disease and Infection Control Departments.

Date Submitted: June 20, 2018

Submitted by: *Arthur E. Crist, Jr., Ph.D.*
Clinical/Technical Director
Microbiology, Immunology, and Molecular Testing
Wellspan Laboratory Services
Ph: 717-851-2393
Email: acrist@wellspan.org